

## **Oxlumo**

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to <a href="do-not\_call@cvscaremark.com">do\_not\_call@cvscaremark.com</a>. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	
<b>Referring</b> Provider Info: ☐ Same as R	equesting Provider
Name:	
Fax:	Phone:
	eferring Provider 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
	t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:	kg
Patient Height:	cm

	e of Service Questions: Where will this drug be administered?		
	☐ Ambulatory surgical, skip to Clinical Questions☐ Off-campus Outpatient Hospital☐ Plansing of the Above the Computer of the	☐ Home infusion, skip to Clinical Questions ☐ On-campus Outpatient Hospital ☐ Pharman Air to Clinical Operations	
D	☐ Physician office, <i>skip to Clinical Questions</i>	☐ Pharmacy, skip to Clinical Questions	
Б.	Is this request to continue previously established treatment with the requested medication?  ☐ Yes - This is a continuation of an existing treatment.  ☐ No - This is a new therapy request (patient has not received requested medication in the last 6 months). skip to Clinical Criteria Questions		
C.	Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids or other pre-medications) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after administration? <i>ACTION REQUIRED: Attach supporting clinical documentation</i> . □ Yes, <i>skip to Clinical Criteria Questions</i> □ No		
D.	Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? <i>ACTION REQUIRED: Attach supporting clinical documentation.</i> $\square$ Yes, <i>skip to Clinical Criteria Questions</i> $\square$ No		
E.	. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? <i>ACTION REQUIRED: Attac supporting clinical documentation.</i> $\square$ Yes $\square$ No		
<u>Cri</u>	iteria Questions:		
1.	What is the diagnosis?		
	☐ Primary hyperoxaluria type 1 (PH1) ☐ Other		
2.	What is the ICD-10 code?		
3.	<ul> <li>Does the patient have a documented diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by either of the following? Action Required: Supporting chart note(s) for molecular genetic tests showing a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene or for liver enzyme analysis demonstrating absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity, must be available upon request.</li> <li>Molecular genetic test showing a mutation in the alanine:glyoxulate aminotransferase (AGXT) gene</li> <li>Liver enzyme analysis demonstrating absent or significantly reduced alanine:glyoxylate aminotransferase (AGT) activity</li> <li>Yes □ No</li> </ul>		
4.	Is the patient currently receiving treatment with the rec	quested drug?	
5.	Has the patient's urinary and/or plasma oxalate decrea  ☐ Yes ☐ No ☐ Unknown No further questions	sed or normalized since initiation of therapy?	
	ttest that this information is accurate and true, an formation is available for review if requested by C		
X_	and a later to the	But ( 1111 )	
Pre	escriber or Authorized Signature	Date (mm/dd/yy)	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oxlumo SOC SGM 4395-A - 11/2022.